The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of respiratory syncytial virus (RSV ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The importance of biosimilars only continues to ...

including the US, Japan and Europe. ABL Bio previously entered into a global licensing agreement with GSK to develop treatments for neurodegenerative diseases.

Read Our Latest Stock Report on Bio-Rad Laboratories Bio-Rad Laboratories Stock Performance BIO opened at $245.23 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6 ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

Landos Biopharma's Omilancor (BT-11) is in Phase II and acts via LANCL2, while AVB-114 from Avobis Bio/Alimentiv is also in Phase II. Abivax S.A.'s Obefazimod (ABX464) is being studied for its ...

$80,000 of BIO-RAD LABORATORIES lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to biomedical research ...